AngioLab is a bio-venture company which has developed a medicine with angiogenesis inhibitors for treating angiogenesis-related diseases.

Since its inception in 1999, AngioLab has been steadfast in its commitment to the development of angiogenesis inhibitors aimed at treating a range of diseases related to angiogenesis.

Leveraging our expertise in oral angiogenesis inhibitors, AngioLab has successfully carried out Phase II clinical trials for several conditions, including neovascular age-related macular degeneration, abdominal obesity, metabolic dysfunction-related steatohepatitis, otitis media with effusion, and periodontitis. These trials were conducted to ascertain both the safety and efficacy of our products.

Furthermore, we have pioneered the development of Ob-X, a health functional food that inhibits angiogenesis. This innovative product has been acknowledged as a functional ingredient with health claim by the MFDS. It is currently available in Korea and has been exported to numerous countries worldwide.

AngioLab is committed to enhancing the quality of life by developing treatments for intractable diseases. Our ultimate goal is to assist individuals in leading long, healthy lives, free from diseases.

We deeply appreciate your ongoing support and look forward to continuing our journey towards making significant contributions to healthcare and medicine.